Comparative Pharmacology
Head-to-head clinical analysis: OVULEN 28 versus YASMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVULEN 28 versus YASMIN.
OVULEN-28 vs YASMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive that inhibits ovulation primarily by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, and altering cervical mucus and endometrial lining.
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins, inhibiting ovulation. Drospirenone has antimineralocorticoid activity, reducing water retention, and antiandrogenic activity.
One tablet (ethinyl estradiol 0.05 mg / ethynodiol diacetate 1 mg) orally once daily for 21 days followed by 7 days placebo; continuous cycle.
One tablet (ethinyl estradiol 0.03 mg / drospirenone 3 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (mean ~17 hours); Norethindrone: 5-14 hours (mean ~8 hours). Clinical context: Steady state reached within 5-7 days.
Terminal elimination half-life is approximately 30 hours for drospirenone; steady-state concentration is achieved after 10 days of daily dosing.
Renal: ~50% as metabolites; Fecal/biliary: ~40% as conjugated metabolites; <1% unchanged in urine.
Approximately 40% renal and 60% fecal after oral administration; metabolites are excreted as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive